Biocon Secures 10-Year Supply Contract For Pertuzumab In Brazil

Biocon Limited, an innovation-led global biopharmaceuticals company, today announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s Productive Development Partnership (PDP) program.

The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil’s 10-year PDP program for Pertuzumab.

The PDP provides the consortium exclusive access to Brazil’s public healthcare market, which accounts for approximately 70% of the country’s demand for Pertuzumab. It also supports the long-term adoption of Biocon’s product within Brazil’s public oncology network.

Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.

Shreehas Tambe, CEO & Managing Director, Biocon, said, “Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines. This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale. In partnership with Bahiafarma and Bionovis, we are bringing together science, innovation, manufacturing excellence and local expertise to create a more sustainable pathway for access to this important cancer therapy. Together, we are not only supporting better patient outcomes but also helping build a stronger, more resilient healthcare ecosystem in Brazil.”

Ceuci Nunes, CEO, Bahiafarma, said, “We celebrate the conclusion of this stage with the certainty that we are advancing in a strategic project for public health. It is the result of a work built in partnership and that paves the way for the incorporation of a highly complex technology, contributing to Brazil strengthening its capacity to produce essential medicines for its Unified Health System (SUS).”

Odnir Finotti, CEO, Bionovis, said, “Through our partnerships with Biocon and Bahiafarma, we reinforce our commitment to the public policies of the Health Economic-Industrial Complex and to Productive Development Partnerships, expanding the Brazilian population’s access to highly complex biological medicines, generating incomes, employing specialized professionals, and promoting the country’s productive autonomy.”

Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Currently, the product is not manufactured locally in Brazil and is a significant expenditure for the country’s Unified Health System (SUS).

Bahiafarma is a public pharmaceutical laboratory of the State of Bahia, Brazil, focused on pharmaceutical research, technological development, innovation and the production and supply of medicines and other health products, particularly for Brazil’s SUS. Bionovis is a Brazilian biotechnology company focused on developing, manufacturing and commercializing complex biological medicines and biosimilars, with a strong emphasis on technology transfer, local biopharmaceutical manufacturing and expanding access to advanced therapies in Brazil.

About Biocon Limited
Biocon Limited is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. For more information, visit www.biocon.com.